dose regimen – Communicable Diseases Research

Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases

Article

Published on 2022-11-022022-11-15
Journal: Rheumatology (Oxford, England)
[Category] SARS, 진단,

RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice

SARS-CoV-2에 대한 2개의 항원 소단위 단백질 백신 후보인 RelCoVax®는 마우스에서 강력한 면역 반응을 유도합니다

Article

Published on 2022-07-302022-09-11
Journal: Vaccine
[Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법,

[키워드] adjuvant adjuvants Administered alum aluminum aluminum hydroxide Antibody titer Antibody titers Antigen antigen exposure Cell Cellular immune response cellular immune responses Combination contribute COVID-19 pandemic CpG Delta delta variant demonstrated develop dominant dose regimen dual E. coli effective vaccine elicited Emergency use authorization evade evidenced glycoprotein heterologous expression hydroxide IFN-γ immune responses immunize immunized immunized mice in vitro induce mammalian cell mammalian cells mice Mutation N protein N proteins neutralize Neutralizing antibodies neutralizing antibody nucleocapsid prime and boost Protein RBD Receptor binding domain Region RelCoVax® S protein Safe SARS-CoV-2 SARS-CoV-2 viral SARS-CoV-2 virus serum splenocyte splenocytes stimulated strain strong immune response subunit Subunit vaccine Subunit vaccine. Th1 the SARS-CoV-2 virus vaccinated individuals Vaccine vaccine candidate vaccine candidates variants of SARS-CoV-2 viral strains virus entry
[DOI] 10.1016/j.vaccine.2022.06.026 PMC 바로가기 [Article Type] Article

A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection

단일 T 세포 에피토프를 사용한 세 번째 백신 접종은 SARS-CoV-2 감염의 쥐 모델에서 보호를 제공합니다

Article

Published on 2022-07-082022-09-12
Journal: Nature Communications
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,

Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis

COVID-19 환자 치료에서 토실리주맙과 코르티코스테로이드 요법의 효능 비교: 체계적인 검토 및 메타 분석

Review

Published on 2022-06-012022-09-12
Journal: Daru : journal of Faculty of Pharmacy, Tehran Univ
[Category] COVID19(2023년), SARS, 진단,

[키워드] 95%CI baseline characteristics Case-control case-control studies case-control study Combination contributed Corticosteroid corticosteroid therapy COVID-19 database determinant Dexamethasone did not reduce dose regimen drug Drug efficacy Efficacy Factor High dose identify IMPROVE mechanical ventilation Meta-analysis Methylprednisolone Mortality outcome Patient patients pulse Randomized Randomized controlled trial randomized trials RCT RCTs reduce reducing mortality reduction searched severe COVID-19 patients shown significantly systematic review therapeutic therapy Tocilizumab tocilizumab. treating COVID-19 was performed
[DOI] 10.1007/s40199-021-00430-8 PMC 바로가기 [Article Type] Review

Should We Delay the Second COVID-19 Vaccine Dose in Order to Optimize Rollout? A Mathematical Perspective

롤아웃을 최적화하기 위해 두 번째 COVID-19 백신 접종을 연기해야 합니까? 수학적 관점

Public Health Archive

Published on 2022-01-242022-09-10
Journal: International Journal of Public Health
[Category] MERS, SARS, 변종,

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines

Research Article

Published on 2021-11-102022-10-30
Journal: Microbiology Spectrum
[Category] COVID-19,

[키워드] age and gender antibodies antibody antibody kinetics Antibody Response average binding domain BNT162b2 BNT162b2 vaccine changes in clinically clinician Cohort COVID-19 COVID-19 pandemic defined difference dosage dose regimen elicited first dose Follow-up human cell IgG IgG antibody IgG response immune system immunization immunosuppressive drugs linear Moderna mRNA mRNA platform mRNA vaccine mRNA-1273 mRNA-1273 vaccine overcome participant peaked Pfizer/BioNTech powerful tool Prospective regimens regression modeling remained response S-protein SARS-CoV-2 SARS-CoV-2 vaccine second dose seroconverted serological Serologically seronegative participants significantly higher Spike protein the SARS-CoV-2 the vaccine titer translated vaccination Vaccine Vaccines virus spike protein was used were measured
[DOI] 10.1128/Spectrum.01162-21 PMC 바로가기 [Article Type] Research Article

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

청소년 및 노인의 SARS-COV-2 재조합 스파이크 단백질 백신 (NVX-COV2373)의 상이한 용량 요법 : 2 상 무작위 위약 대조 시험

Clinical Trial

Published on 2021-10-012022-08-13
Journal: PLoS Medicine
[Category] Biochemistry, MERS, SARS, 임상, 진단,

[키워드] 95% CI 95% confidence interval accumulate addition Administered Adults adverse events age Anti-spike Antibody Response assessments assigned composed conducted convalescent sera coronavirus Day dose dose regimen Efficacy Endpoint Enrollment exceeded Follow-up Formica Frequency full-length SARS-CoV-2 geometric mean geometric mean titer geometric mean titers GMTs group groups identify IgG immune persistence immune response immune responses immunogenic immunogenicity Immunoglobulin Immunoglobulin G include inhibitory concentration intensity intramuscular dose lack limitation Matrix-M1 adjuvant median Mild mild to moderate moderate neutralizing antibody Neutralizing antibody response neutralizing antibody responses NVX-CoV2373 occurred less Older Older adults participant Participants Phase 1 Phase 2 Placebo placebo-controlled placebo-controlled trial primary endpoints Protein Randomized randomized placebo-controlled trial Randomly reactogenicity receive Recombinant spike protein regimen researcher respiratory Respiratory Coronavirus robust safety follow-up SARS-CoV-2 second dose second vaccination secondary endpoint seroconversion rate seroconversion rates severity short duration spike glycoprotein spike glycoproteins Spike protein Support The United States These data Tolerability Treatment Trial Trial registration trimeric United States USA vaccination Vaccine vaccine group wild-type virus
[DOI] 10.1371/journal.pmed.1003769 PMC 바로가기 [Article Type] Clinical Trial

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

SARS-CoV-2 mRNA 백신(BNT162b2) 2회 접종 후 의료 전문가의 조기 항체 반응

Multicenter Study

Published on 2021-09-012022-09-11
Journal: Clinical microbiology and infection : the official
[Category] SARS, 임상, 진단, 치료법,

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-spike antibodies anti-spike antibody antibody Antibody Response Antibody titre antibody titres baseline Belgium blood sample Blood samples BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine clinical trial collected conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine disease dose dose regimen hcp health-care Humoral response immune response individual individuals infected individual infected individuals lead mRNA vaccine multicentre nucleocapsid of BNT162b2 optimum dose professional reached Receptor binding domain respiratory S1 subunit SARS-CoV-2 SARS-CoV-2 nucleocapsid second dose seronegative severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly higher single dose Spike protein Support the S1 subunit the SARS-CoV-2 the spike protein titre two-dose regimen uninfected Vaccine vaccine. Volunteer were excluded were measured
[DOI] 10.1016/j.cmi.2021.05.004 PMC 바로가기 [Article Type] Multicenter Study

One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model

SARS-CoV-2 합성 DNA 백신 INO-4800의 1회 또는 2회 투여 요법은 비인간 영장류 챌린지 모델에서 호흡기 질환 부담으로부터 보호

Article

Published on 2021-08-092022-09-12
Journal: Vaccine
[Category] MERS, SARS, 비임상, 진단,

Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

건강한 성인의 코로나바이러스 질병 2019에 대한 재조합 융합 단백질 백신(V-01)의 면역원성과 안전성: 무작위 배정, 이중 맹검, 위약 대조, 2상 시험

Clinical Trial

Published on 2021-07-222022-09-12
Journal: Chinese medical journal
[Category] SARS, 임상, 진단,

[키워드] acute respiratory syndrome Adults adverse event AEs age anti-RBD Antigen appear China clinical trial clinical trials confidence interval Control convalescent serum coronavirus coronavirus disease COVID-19 COVID-19 patient demonstrated distribution dose regimen dosing regimens double-blind Efficacy elevated Endpoint Frequency fusion protein geometric mean titer group Guangdong healthy IFN-PADRE-RBD-Fc dimer immune response immune responses immunization immunogenic immunogenicity Immunoglobulin imperative indicated initiated injection intramuscularly less mild in severity neutralizing antibody Older pandemic participant peaked percentage Phase I Placebo placebo-controlled Preliminary data preliminary finding prevention primary immunogenicity Randomized RBD reactogenicity receive Receptor binding domain recombinant COVID-19 vaccine recombinant fusion protein recruited regimen remained robust Safe safety profile significantly specific binding antibody Support symptomatic Trial two-dose regimen V-01 Vaccine vaccine candidate Vaccines
[DOI] 10.1097/CM9.0000000000001702 PMC 바로가기 [Article Type] Clinical Trial